These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 6220307)

  • 21. Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapy.
    Alexanian R; Migliore PJ
    J Lab Clin Med; 1970 Feb; 75(2):225-33. PubMed ID: 5414404
    [No Abstract]   [Full Text] [Related]  

  • 22. Carcinoma of the breast. Occurence after treatment with melphalan for multiple myeloma.
    Bell R; Sullivan JR; Fone DJ; Hurley TH
    JAMA; 1976 Oct; 236(14):1609-10. PubMed ID: 183029
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of multiple myeloma with melphalan: 35 personal cases].
    Dryll A; Ryckewaert A; Kahn MF; Hayat M; de Seze S
    Sem Hop; 1970 Jan; 46(5):289-98. PubMed ID: 4327260
    [No Abstract]   [Full Text] [Related]  

  • 24. Multiple myeloma terminating in acute leukemia: report of two cases and review of the literature.
    Martínez-Poventud G; Fernández AC; Vélez-García E
    Bol Asoc Med P R; 1985 Oct; 77(10):419-21. PubMed ID: 3865657
    [No Abstract]   [Full Text] [Related]  

  • 25. Intermittent melphalan therapy in multiple myeloma.
    Hoogstraten B; Costa J; Cuttner J; Forcier J; Leone LA; Harley JB; Glidewell OJ
    JAMA; 1969 Jul; 209(2):251-3. PubMed ID: 5819231
    [No Abstract]   [Full Text] [Related]  

  • 26. [Refractory anemia with partial myeloblastosis in multiple myeloma treated with melphalan].
    Morlock G; Bataille R; Sany J; Serre H
    Sem Hop; 1977 Apr 9-16; 53(14-15):853-6. PubMed ID: 194338
    [No Abstract]   [Full Text] [Related]  

  • 27. Breast cancer and acute leukemia in a patient with multiple myeloma treated with melphalan.
    Meytes D; Katz DR
    Isr J Med Sci; 1973 Aug; 9(8):1044-7. PubMed ID: 4753846
    [No Abstract]   [Full Text] [Related]  

  • 28. [Dysmyelopoietic syndrome 7 years after melphalan treatment of multiple myeloma. Clinical case].
    Scolozzi R; Boccafogli A
    Minerva Med; 1983 Jul; 74(28-29):1783-5. PubMed ID: 6866310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.
    Borad MJ; Swift R; Berenson JR
    Leukemia; 2005 Jan; 19(1):154-6. PubMed ID: 15496977
    [No Abstract]   [Full Text] [Related]  

  • 30. Cyclophosphamide vs melphalan in treatment of plasma cell myeloma.
    Rivers SL; Patno ME
    JAMA; 1969 Feb; 207(7):1328-34. PubMed ID: 4179565
    [No Abstract]   [Full Text] [Related]  

  • 31. [Acute myeloproliferative syndrome after alkylating agent treatment in a case of multiple myeloma].
    Gardella S; Cervantes F; Bladé J; Brugués R; Rozman C
    Med Clin (Barc); 1982 Sep 1-15; 79(4):185-8. PubMed ID: 7144293
    [No Abstract]   [Full Text] [Related]  

  • 32. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.
    Offidani M; Marconi M; Corvatta L; Olivieri A; Catarini M; Leoni P
    Haematologica; 2003 Dec; 88(12):1432-3. PubMed ID: 14688003
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.
    Roy V; Stewart AK; Bergsagel PL; Dispenzieri A; Laumann K; Allred J; Lacy MQ; Fonseca R; Reeder CB; Kumar S; Rivera CE; Gertz MA; Buadi FK; Hayman SR; Rajkumar SV
    Blood Cancer J; 2015 Mar; 5(3):e294. PubMed ID: 25794130
    [No Abstract]   [Full Text] [Related]  

  • 34. Leukaemia on myeloma.
    Webb JA; Bateman CJ; Davies JD
    Br Med J; 1971 Oct; 4(5781):231. PubMed ID: 5286613
    [No Abstract]   [Full Text] [Related]  

  • 35. [Indications for chemotherapy in multiple myeloma].
    Heyll A; Aul C
    Dtsch Med Wochenschr; 1996 May; 121(20):675. PubMed ID: 8635404
    [No Abstract]   [Full Text] [Related]  

  • 36. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
    J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple myeloma and acute myelomonocytic leukemia.
    Kyle RA; Pierre RV; Bayrd ED
    N Engl J Med; 1970 Nov; 283(21):1121-5. PubMed ID: 5273282
    [No Abstract]   [Full Text] [Related]  

  • 38. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Erythroleukemia in multiple myeloma. A case report].
    Streuli R; Voellmy W
    Schweiz Med Wochenschr; 1987 Feb; 117(8):286-91. PubMed ID: 3470922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.